Research programme: breast cancer therapeutics - imMAGE Biotherapeutics

Drug Profile

Research programme: breast cancer therapeutics - imMAGE Biotherapeutics

Alternative Names: DNA based Vaccine/Anti-CTL4 - Immage Biotehrapeutics; DNA based Vaccine/Anti-PD-L1 - Immage Biotehrapeutics; IMT 001

Latest Information Update: 01 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immage Biotherapeutics
  • Class Antineoplastics; Cancer vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer

Most Recent Events

  • 28 Nov 2016 ImMAGE Biotherapeutics announces intention to submit IND to US FDA in 2017
  • 28 Sep 2016 Immage Biotherapeutics in-licenses SMARTmid™ vectors technology from PepVax before September 2016 (Immage Therapeutics pipeline, September 2016)
  • 13 Sep 2016 Preclinical trials in Breast cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top